Nexstim Targets US Stroke Rehab Market With MRI-Guided Transcranial Magnetic Stimulation
This article was originally published in The Gray Sheet
Noninvasive Navigated Brain Therapy system is undergoing a pivotal study in the US to improve brain function following a stroke.
You may also be interested in...
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.